October 23, 2017

Philips highlights the value of advanced molecular imaging at EANM 2017

Innovative solutions enhance and simplify the clinical decision making path, from diagnosis to treatment, to drive more personalized care

Amsterdam, the Netherlands and Vienna, Austria – Royal Philips (NSYE: PHG, AEX: PHIA) today announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation and more personalized care at the European Association of Nuclear Medicine (EANM) Congress 2017. Molecular imaging provides insight into molecular and cellular processes in the body, and has the potential to transform healthcare by offering earlier detection and enabling more precise treatment of diseases. Philips continues to deliver molecular imaging solutions that enhance quantitative accuracy and enable new clinical applications, driving more personalized care and workflow efficiencies from diagnosis to treatment. Philips’ EANM exhibit will feature the company’s latest solutions and technologies driving the future of nuclear medicine with systems like Vereos Digital PET/CT (Positron Emission Tomography/Computed Tomography) system.

The world's first and only fully-digital PET/CT system

As the world's first and only fully-digital PET/CT system, Vereos demonstrates Philips’ commitment to enhance care by delivering improved detectability and characterization of small lesions [1]. Vereos delivers an enhanced patient experience through fast, whole-body scans in under five minutes, and low PET dose [2], all without compromising image quality. Vereos simplifies the clinical decision making process through a fast, more confident path to cancer treatment.

Vereos Digital PET/CT systems are being installed in leading healthcare facilities worldwide. Most recently, Philips installed the digital PET/CT scanner at the Isala Oncology Center in the Netherlands. “Isala is proud to be one of the first five hospitals in the world to have the digital PET/CT system installed,” said Daniëlle Koopman, technical medicine physician of Isala Oncology center.

“Molecular imaging today allows physicians to make decisions with greater insight, precision and confidence, bringing healthcare one step closer to personalized care,” said Kees Wesdorp, Business Group Lead Diagnostic Imaging. “Philips has made a lasting impact in molecular imaging by providing clinicians with innovations such as Time-of-Flight PET and digital PET/CT. This year at EANM we are showing how we’re innovating to simplify the path to clinical decision-making, enhancing value for imaging teams, health systems and most critically, patients.”

Molecular imaging today allows physicians to make decisions with greater insight, precision and confidence, bringing healthcare one step closer to personalized care.

Kees Wesdorp

Business Group Lead Diagnostic Imaging

Driving the future of advanced molecular imaging

At EANM 2017, Philips features its latest solutions and technologies that are driving the future of advanced molecular imaging, including:

Vereos Digital PET/CT – Featuring Philips proprietary Digital Photon Counting (DPC) technology, Vereos offers improved detectability and characterization of small lesions [1]. The system provides uncompromised detectability and quantification at half the PET dose [2]. Vereos also provides lesion detectability in one-tenth of the time [3].
Ingenuity TF PET/CT – Ingenuity TF PET/CT leverages Philips’ Astonish TF technology for enhanced image contrast, resolution, and quality. It also features Philips’ proprietary xPand5 quantification tools to assist in measuring and monitoring disease progression. These technologies are combined with advanced CT features, such as iPatient, iDose⁴ and metal artifact reduction for implants (O-MAR), to drive confidence and consistency through personalized patient centric workflow.
SPECT solutions – CardioMD IV and BodyMD [4] – Cost-efficient cardiac and general purpose SPECT solutions to maximize the return on investment.
IntelliSpace Portal 9.0 – The latest edition of Philips’ comprehensive, advanced visualization and analysis platform offers quantitative tumor tracking and treatment response tools with a streamlined workflow for follow‐up and analysis in oncology cases. IntelliSpace Portal 9.0 provides enterprise‐wide access to a comprehensive suite of Molecular Imaging processing and review applications for general Nuclear Medicine, SPECT, SPECT/CT and PET/CT.

Driving conversation on innovation

This year, Philips hosts a number of talks and presentations in a live forum format at its booth at EANM. In addition, Philips’ academic partners present 10 scientific presentations and posters demonstrating the value that Philips’ digital PET/CT system is bringing to molecular imaging—advancing knowledge and application using features such as lesion detection and quantitative imaging.

For more information on Philips' molecular imaging solutions, and to learn more about the company’s presence at EANM, visit booth 402, www.philips.com/eanm and follow the conversation on @PhilipsLiveFrom.

[1] Nguyen NC, Image Quality and Diagnostic Performance of a Digital PET Prototype in Patients with Oncologic Diseases: Initial Experience and Comparison with Analog PET, J Nucl Med 2015; 56:1378–1385.

[2] Liu X et al, Impact of FDG Dose Reduction on Lesion Quantification in Dynamic PET: A Simulation Study Based on Clinical Trial Data, SNMMI 2016.

[3] Zhang J., Evaluation of speed of PET acquisition: How fast can we go? - A validation of list mode PET simulation approach with true acquisitions, SNMMI 2017.

[4] CardioMD IV and BodyMDBody MD are not available in all markets. Please contact your local Philips sales representative for availability in your country.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 73,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Click here to read more Click here to read less